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Abstract
Cruentaren A, an antifungal benzolactone produced by the myxobacterium Byssovorax cruenta, is
highly cytotoxic against various human cancer cell lines and a highly selective inhibitor of
mitochondrial F-ATPase. A convergent and efficient synthesis of cruentaren A is reported, based
upon a diastereoselective alkylation, a series of stereoselective aldol reactions utilizing Myers’
pseudoephedrine propionamide, an acyl bromide–mediated esterification and a ring-closing
metathesis (RCM) as the key steps. The RCM reaction was applied for the first time towards the
total synthesis of cruentaren A, which led to a convergent and efficient synthesis of the natural
product.
Cruentaren A and its isomeric analogue, cruentaren B, have been identified as the first novel
structures isolated from the fermentation broths of Byssovorax cruenta by Hofle et al.1,2
Cruentaren A (1) was the major natural product, which was isolated through bioassay guided
fractionation that focused upon the identification of novel antifungal and cytotoxic agents.
While cruentaren A demonstrated potent cytotoxic effects (IC50 of 8.3 nM against L929
mouse fibroblasts), its closely related derivative, cruentaren B, was only marginally active.3
Cruentaren A is a member of the growing class of benzolactone natural products that
contains a resorcinol derived 12-membered macrocyclic lactone and an N-acylallylamine
side chain (Figure 1).4 Despite structural similarities to other natural products of this class,
cruentaren A possesses a unique mechanism of action. This natural product induces
cytoxicity through selective inhibition of F-ATPase, but is devoid of inhibitory activity
against other ATPases.1–3
Due to the interesting architecture and a unique biological profile, cruentaren A has attracted
significant attention from the synthetic community. Four successful total syntheses and
numerous approaches to fragments have been reported.5,6,7,8 In fact, all published syntheses
rely upon the ring-closing alkyne metathesis (RCAM) reaction as a key step, followed by
Lindlar reduction to introduce the cis-olefin that is present within the macrocyclic ring. Due
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to the publication of prior existing routes, we pursued an alternate method that does not rely
upon the RCAM in an effort to ultimately produce analogs that are not easily obtained
through other routes. Herein, we report the total synthesis of cruentaren A that utilizes the
RCM reaction for construction of the desired cis-macrocyclic product.
Retrosynthetic analysis of cruentaren A (1), utilizing the RCM reaction for construction of
the 12-membered lactone, required fragments 2 and 3 as relevant synthons. Weinreb amide 5
could then be reacted with the benzylic anion of 6 to provide ketone intermediate 4, which
would enable subsequent metathesis to form 2. Likewise, esterification of secondary alcohol
7 would provide substrate 6 and after RCM, the macrocycle. Staudinger ligation between the
allylazide of 2 and acid 3 was envisioned to occur before global deprotection to provide the
natural product. Successful stereochemical induction with Myers’ pseudoephedrine chiral
auxiliary would be required throughout this synthetic strategy. Specifically, the synthesis of
allyl alcohol 7 was envisioned to depend upon Myers’ psueodoephedrine to construct all
three stereocenters through sequential reactions (Figure 2). Myers’ psueodoephedrines are
readily available from inexpensive, commercially available reagents via a simple one step
process and furthermore, these chiral auxiliaries can be elaborated into a variety of useful
entities through well-described synthetic protocols.9
In the event, alkylation of (S,S)-pseudoephedrine propionamide 9 with cis-allyl bromide 810
proceeded smoothly under Myers’ optimized conditions11 to provide the diastereomerically
enriched methyl amide 10 (>20:1), which upon subsequent lithium aluminium hydride
reduction gave the corresponding aldehyde, 11. Induction of stereochemistry at C-16 and
C-17 was accomplished through use of a zirconium-mediated aldol reaction9 between the
(Z)-enolate of propionamide 12 and aldehyde 11 to give diastereomerically pure 13 (Scheme
1).
Carboxylic acid 14 was accessed by mild hydrolysis of 13 followed by conversion to the
Weinreb amide 15 using the (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate (COMU) coupling reagent. COMU is a 3rd
generation uronium-type coupling reagent that is commonly used for solution-phase peptide
synthesis; the by-products produced with COMU are water soluble and easily removed.
Furthermore, COMU exhibits a less hazardous safety profile than benzotriazole-based
reagents and prevents recemization during the coupling event.12 The secondary alcohol of
15 was protected as the tert-butyldimethylsilyl ether before subsequent reduction of the
amide to give aldehyde 17. Upon treatment of 17 with in situ generated Soderquist’s
allylborane intermediate that was generated upon exposure of allyl Grignard to 18,13 a
highly enantio-enriched homoallylic alcohol 7 was produced with excellent facial
selectivity.
Stereochemical assignment of advanced intermediate 7 was accomplished by Mosher’s ester
analysis,14 which validated the desired syn stereochemistry of the 1,3-diol relationship for 7.
To determine the relative stereochemical relationship of the C-16 methyl group, acid-
mediated TBS hydrolysis and subsequent acetonide protection of the resultant 1,3-diol
enabled formation of 19, which was shown to exhibit the correct stereochemical relationship
as deterimined by Rynchnovsky’s method (Scheme 2).15
The synthetic route to provide Weinreb amide fragment 5 was straightforward and provided
a rapid means to generate significant quantities of this intermediate for the optimization of
latter steps. Alkylation of propionamide 12 with allyl bromide under Myers’ conditions
generated α-methyl amide, 20 (dr >20:1). Hydrolysis and subsequent COMU-mediated
coupling produced Weinreb amide 5 without loss of enantioenrichment on multi gram scale.
A similar zirconium-mediated aldol reaction between propionamide 9 and butanal as
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described above to provide amide 22 followed by hydrolysis, gave carboxylic acid 3 without
diastereomeric loss. The successful COMU-mediated coupling reaction16 suggested that the
hydroxyl group of compound 3 did not require protection. Therefore, the free alcohol of 3
was left unprotected (Scheme 3).
Construction of the macrocyclic ring involved esterification of allylic alcohol 7 with
commercially available benzoic acid 22. Synthesis of ester 6 proved to be challenging and
unsuccessful results were obtained following the methods reported by Furstner and
Vintonyak for the related alkynyl derivative.4,5 After a significant investment of time and
effort, synthesis of ester 6 was finally achieved upon treatment of acid 2 with oxalyl
bromide (COBr)2, DIPEA, and catalytic DMF in DCM at 0 °C for 30 min, followed by the
addition of alcohol 3 and 4-(dimethylamino)pyridine (DMAP). Complete conversion to
desired ester 6 occurred within 10 min in high yield. Alkylation of 6 with Weinreb amide 5
proceeded by generation of the benzylic anion of 6 to produce advanced intermediate 4 in
reasonable yield (Scheme 4).
Prior to RCM of the terminal olefins, stereoselective reduction of ketone 4 was considered.
Attempts to affect stereoselective reduction of ketone 4 under various conditions enlisting
the CBS reagent were unsuccessful as 4 was highly resistant to reduction under these
constraints. However, reduction of ketone 4 utlizing Noyori’s asymmetric transfer
hydrogenation conditions proved successful.17,18 In the event, ketone 4 was treated with
sodium formate and catalytic RuCl[(S,S)-Tsdpen](p-cymene) in DMF and water to generate
alcohol 23 in quantitative yield and reasonable diastereomeric selectivity (~5:1).
Unfortunately, the epimeric product was not separable via column chromatography at this
stage (Scheme 4).
Consequently, a mixture of diastereomeric alcohols (23) was subjected to RCM catalysis,
and gratifyingly, the cis-olefin containing macrocycle was obtained in diastereomerically
pure form, and the alcohol epimers were readily separable via column chromatography.
Unfortunately, an unexpected side reaction did occur, in which cis to trans isomerization of
the allylic ether side chain was observed. Several solvents, including THF, benzene, and
methanol were screened, however, the most minimal isomerization occured in DCM. The
optimized reaction conditions included the addition of 5 mol% of catalyst at 0 °C to a 0.5
mM solution of alcohol 23 in DCM, followed by warming to 20 °C. RCM was complete
after 3.5 h, but required treatment with saturated aqueous potassium carbonate (K2CO3) for
catalyst deactivation in order to prevent additional isomerization during work-up. These
reaction conditions furnished the epimerically pure cis-macrocyclic product, 24, in 79%
yield as a 4:1 (cis:trans) mixture of the olefinic side chain isomers. Compound 24 was then
sequentially TBS-protected at C-8 to generate 25, followed by PMB-removal to give allyl
alcohol 26.
Conversion of 26 to cruentaren A, and completion of the total synthesis involved four
additional manipulations (Scheme 5). The allylic alcohol of 26 was converted to the
corresponding allyl-azide (2) upon treatment with Zn(N3)2(pyridine)2,19 diisopropyl
azodicarboxylate and triphenylphosphine. One-pot azide reduction and COMU-mediated
amide formation was achieved via Staudinger ligation conditions to provide the protected
variant of cruentaren A (27) as a single diastereomer. Cleavage of the C-3 methyl ether was
achieved by subjecting compound 27 to boron trichloride in DCM at low temperature,
followed by removal of the corresponding bis(TBS-ether) with HF-pyridine in acetonitrile to
furnish cruentaren A (1). The spectroscopic data for synthetic cruentaren A (1) were in
agreement with data reported for the natural product.1
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In summary, a convergent and efficient total synthesis of cruentaren A has been described
with a longest linear sequence of 18 steps. The synthesis is dependent upon the use of
Myers’ diastereoselective alkylation, a series of stereoselective aldol reactions utilizing
pseudoephedrine propionamide, a Soderquist allyaltion, an acyl bromide-mediated
esterification, and RCM as the key steps. Additional studies for cruentaren A and analogues
are currently under investigation with the goal of more thoroughly understanding the role F-
ATPase plays in the maturation of nascent polypeptides.20,21,22 The results from such
studies will be disclosed in due course.
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Benzolactone natural product family.
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Retrosynthtic analysis of cruentaren A (1).
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Synthesis of allylic aclohol 7.
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Stereochemistry confirmation at C-16 carbon.
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Synthesis of the Weinreb amide 5 and side chain acid 3.
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Synthesis of key macrolactone 25.
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Conversion of 25 to cruentaren A (1).
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